4.8 Article

Manipulation of PD-L1 Endosomal Trafficking Promotes Anticancer Immunity

Journal

ADVANCED SCIENCE
Volume 10, Issue 6, Pages -

Publisher

WILEY
DOI: 10.1002/advs.202206411

Keywords

anticancer immunity; endocytosis; endosomal trafficking; extracellular vesicle; PD-L1; Rab5; Rab27

Ask authors/readers for more resources

The aberrant regulation of PD-L1 in tumor cells is poorly understood. This study investigates the endosomal trafficking of plasma membrane PD-L1 in tumor cells and demonstrates that it is Rab5- and clathrin-dependent. Triazine compound 6J1 blocks this trafficking and promotes exosomal PD-L1 secretion by activating Rab27. This research provides new insights into the manipulation of PD-L1 endosomal trafficking.
The aberrant regulation of PD-L1 in tumor cells remains poorly understood. Here, the authors systematically investigate the endosomal trafficking of plasma membrane PD-L1 in tumor cells. They show that plasma membrane PD-L1 is continuously internalized, and then trafficked from early endosomes to multivesicular bodies/late endosomes, recycling endosomes, lysosomes, and/or extracellular vesicles (EVs). This constitutive endocytic trafficking of PD-L1 is Rab5- and clathrin-dependent. Triazine compound 6J1 blocks the endosomal trafficking of PD-L1 and induces its accumulation in endocytic vesicles by activating Rab5. 6J1 also promotes exosomal PD-L1 secretion by activating Rab27. Together, these effects result in a decrease in the membrane level of PD-L1 in 6J1-treated tumor cells and enables tumor cells to be more susceptible to the tumor-killing activity of T cells in vitro. 6J1 also increases tumor-infiltrating cytotoxic T cells and promotes chemokines secretion in the tumor microenvironment. Rab27 knockdown abolishes 6J1-induced PD-L1 secretion in EVs and revokes the exhausted tumor-infiltrating T cells in tumors, thereby improving the anticancer efficacy of 6J1. Furthermore, a combination of 6J1 and an anti-PD-1 antibody significantly improves the anticancer immune response. Therefore, manipulating PD-L1 endosomal trafficking provides a promising means to promote an anticancer immune response in addition to the immune checkpoint-blocking antibody therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available